About this item:

614 Views | 126 Downloads

Author Notes:

Correspondence: Judith L. Fridovich-Keil, Department of Human Genetics, Emory University School of Medicine, Rm. 325.2 Whitehead Bldg, 615 Michael St, Atlanta, GA 30322, USA; Email: jfridov@emory.edu

Acknowledgments: We thank all of the health care professionals and their staff who helped to collect the data reported in this manuscript.

This work is dedicated with admiration to all galactosemia patients and their families.

Disclosures: No conflict of interest.


Research Funding:

This work was supported by the National Institutes of Health grant R01 DK059904 (to JLFK).

Diversity of approaches to classic galactosemia around the world: a comparison of diagnosis, intervention, and outcomes

Show all authors Show less authors


Journal Title:

Journal of Inherited Metabolic Disease


Volume 35, Number 6


, Pages 1037-1049

Type of Work:

Article | Post-print: After Peer Review


Without intervention, classic galactosemia is a potentially fatal disorder in infancy. With the benefit of early diagnosis and dietary restriction of galactose, the acute sequelae of classic galactosemia can be prevented or reversed. However, despite early and lifelong dietary treatment, many galactosemic patients go on to experience serious long-term complications including cognitive disability, speech problems, neurological and/or movement disorders and, in girls and women, ovarian dysfunction. Further, there remains uncertainty surrounding what constitutes a ‘best practice’ for treating this disorder. To explore the extent and implications of this uncertainty, we conducted a small but global survey of healthcare providers who follow patients with classic galactosemia, seeking to compare established protocols for diagnosis, intervention, and follow-up, as well as the outcomes and outcome frequencies seen in the patient populations cared for by these providers. We received 13 survey responses representing five continents and 11 countries. Respondents underscored disparities in approaches to diagnosis, management and follow-up care. Notably, we saw no clear relationship between differing approaches to care and long-term outcomes in the populations studied. Negative outcomes occurred in the majority of cases regardless of when treatment was initiated, how tightly galactose intake was restricted, or how closely patients were monitored. We document here what is, to our knowledge, the first global comparison of healthcare approaches to classic galactosemia. These data reinforce the idea that there is currently no one best practice for treating patients with classic galactosemia, and underscore the need for more extensive and statistically powerful comparative studies to reveal potential positive or negative impacts of differing approaches.

Copyright information:

© SSIEM and Springer 2012

Export to EndNote